New insight into amphotericin B resistance in Aspergillus terreus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1583-1588

  Blum, Gerhard ^a   Hörtnagl, Caroline ^a   Jukic, Emina ^a   Erbeznik, Thomas ^a   Pümpel, Thomas ^a   Dietrich, Hermann ^b   Nagl, Markus ^a   Speth, Cornelia ^a   Rambach, Günter ^a   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMPHOTERICIN B; CATALASE; ERGOSTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; CONTROLLED STUDY; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGAL VIRULENCE; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; OXIDATIVE STRESS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN SECRETION; SURVIVAL RATE; UPREGULATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; LIPID PEROXIDATION; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS;

EID: 84875145526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01283-12     Document Type: Article

References (38)

1. Fridkin S. 2005. The changing face of fungal infections in health care settings. Clin. Infect. Dis. 41:1455-1460.
2. Martino R, Subira M. 2002. Invasive fungal infections in hematology: new trends. Ann. Hematol. 81:233-243.
3. Singh N. 2001. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. 33:1692-1696.
4. Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458.
5. Anaissie E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14:S43-S53.
6. Blum G, Perkhofer S, Grif K, Mayr A, Kropshofer G, Nachbaur D, Kafka-Ritsch R, Dierich MP, Lass-Florl C. 2008. A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clin. Microbiol. Infect. 14:1146-1151.
7. Lass-Flörl C, Grif K, Kontoyiannis DP. 2007. Molecular typing of Aspergillus terreus isolates in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J. Clin. Microbiol. 45:2686-2690.
8. Lass-Flörl C, Rath PM, Niederwieser D, Kofler G, Würzner R, Kreczy A, Dierich MP. 2000. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J. Hosp. Infect. 46:31-35.
9. Varga J, Toth B, Kocsube S, Farkas B, Szakacs G, Teren J, Kozakiewicz Z. 2005. Evolutionary relationships among Aspergillus terreus isolates and their relatives. Antonie van Leeuwenhoek 88:141-150.
10. Abraham O, Manavathu E, Cutright JL, Chandrasekar PH. 1999. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbiol. Infect. Dis. 33:7-11.
11. Espinel-Ingroff A, Arthington-Skaggs BA, Igbal N, Ellis D, Pfaller M, Messer SA, Rinaldi M, Fothergill A, Gibbs D, Wang A. 2007. A multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin-B and caspofungin. J. Clin. Microbiol. 45: 1811-1820.
12. Steinbach W, Benjamin D, Kontoyiannis D, Perfect J, Lutsar I, Marr K, Lionakis M, Torres H, Jafri H, Walsh T. 2004. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis. 39:192-198.
13. Abu-Salah KM. 1996. Amphotericin B: an update. Br. J. Biomed. Sci. 53:122-133.
14. Finkelstein A, Holz R. 1973. Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. Membranes 2:377-408.
15. Reeves EP, Murphy T, Daly P, Kavanagh K. 2004. Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus. J. Med. Microbiol. 53:719-725.
16. Vanden Bossche H, Warnock DW, Dupont B, Kerridge D, Sen GS, Improvisi L, Marichal P, Odds FC, Provost F, Ronin O. 1994. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32:189-202.
17. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. U. S. A. 109:2234-2239.
18. Seo K, Akiyoshi H, Ohnishi Y. 1999. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol. Immunol. 43:1017-1025.
19. Sokol-Anderson M, Brajtburg J, Medoff G. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154:76-83.
20. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
21. Clinical and Laboratory Standards Institute2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI Document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:5150-5154.
23. Balajee SA, Baddley JW, Peterson SW, Nickle D, Varga J, Boey A, Lass-Florl C, Frisvad JC, Samson RA. 2009. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryot. Cell 8:713-722.
24. Wang L, Yokoyama K, Miyaji M, Nishimura K. 2001. Identification, classification, and phylogeny of the pathogenic species Exophiala jeanselmei and related species by mitochondrial cytochrome b gene analysis. J. Clin. Microbiol. 39:4462-4467.
25. Yaguchi T, Horie Y, Tanaka R, Matsuzawa T, Ito J, Nishimura K. 2007. Molecular phylogenetics of multiple genes on Aspergillus section Fumigati isolated from clinical specimens in Japan. Nihon Ishinkin. Gakkai Zasshi. 48:37-46.
26. Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW. 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45:85-93.
27. Rössner H. 1993. Fungal biomass by ergosterol content, p 49-51. In Methods in soil biology. Springer, Berlin, Germany.
28. Egger P, Bellmann R, Wiedermann CJ. 2001. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 760:307-313.
29. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
30. Thienpont LM, Van Nuwenborg JE, Stockl D. 1995. Ion chromatography as potential reference methodology for the determination of total sodium and potassium in human serum. J. Chromatogr. A 706: 443-450.
31. Aebi H. 1984. Catalase in vitro. Methods Enzymol. 105:121-126.
32. Pullar JM, Winterbourn CC, Vissers MC. 1999. Loss of GSH and thiol enzymes in endothelial cells exposed to sublethal concentrations of hypochlorous acid. Am. J. Physiol. 277:H1505-H1512.
33. Peever TL, Higgins VJ. 1989. Electrolyte leakage, lipoxygenase, and lipid peroxidation induced in tomato leaf tissue by specific and nonspecific elicitors from Cladosporium fulvum. Plant Physiol. 90:867-875.
34. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. 2000. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J. Med. Microbiol. 49:601-606.
35. Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch R, Bard M, Rogers PD. 2004. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimicrob. Chemother. 54:376-385.
36. Deak E, Wilson SD, White E, Carr JH, Balajee SA. 2009. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLoS One 4:e7673. doi:10.1371/journal. pone.0007673.
37. Walsh T, Petraitis V, Petraitiene R, Field-Ridely A, Sutton DA, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi M, Lyman CA. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319.
38. Vaidyanathan VV, Sastry PS, Ramasarma T. 1993. Regulation of the activity of glyceraldehyde 3-phosphate dehydrogenase by glutathione and H2O2. Mol. Cell. Biochem. 129:57-65.